Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B47a35a3a1eaaed3860579d896e56dd8e> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B47a35a3a1eaaed3860579d896e56dd8e NCIT_P378 "NCI" @default.
- B47a35a3a1eaaed3860579d896e56dd8e type Axiom @default.
- B47a35a3a1eaaed3860579d896e56dd8e annotatedProperty IAO_0000115 @default.
- B47a35a3a1eaaed3860579d896e56dd8e annotatedSource NCIT_C160780 @default.
- B47a35a3a1eaaed3860579d896e56dd8e annotatedTarget "A preparation of autologous T-lymphocytes that have been genetically engineered to express a single-domain antibody that recognizes human mesothelin, fused to the N-terminus of the CD3-epsilon T-cell receptor (TCR) subunit which, upon expression is incorporated into the endogenous TCR complex, with potential antineoplastic activity. Upon administration, gavocabtagene autoleucel specifically target and bind to mesothelin-expressing tumor cells. This leads to T-cell activation and T-cell mediated lysis of mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. Compared to chimeric antigen receptor (CAR) T-cells, TRuCs may be associated with less pro-inflammatory cytokine secretion and fewer adverse effects without compromising therapeutic efficacy." @default.